Central Nervous System (CNS) | Drug Research, Discovery & Development | Charles River

central nervous system  

 
 

With an aging population, better rates of diagnosis, and an increase of central nervous system diseases after the age of 65, there is a mounting need to discover and develop more innovative and effective therapeutic treatments focused on the central nervous system.

Charles River offers a wide range of services supported by our scientific depth, unique technical capabilities, and experience in all the major neurodegenerative diseases and neurological indications, such as Alzheimer’s disease, Parkinson’s disease, chronic pain, epilepsy, Multiple Sclerosis, stroke, and more. From animal models of disease and preclinical testing to clinical trials, we have developed the tools to assist clients in shortening the development cycle of compounds with neurological implications. 

Discover the full range of Charles River Products and Services

For more information please call:

(Country Code)+800.3195.3430
askcharlesriver@crl.com

view all
Cerebricon brings together MRI techniques, biomarkers and behavioral measurements in gold standard assays for acute neurology (e.g., stroke and spinal cord injury), chronic neurology (e.g., multiple sclerosis and Alzheimer’s and Parkinson’s disease) and psychiatry (exemplified by ADHD, schizophrenia and depression).

News & Events

view all
mars 01 - New Technical Resources Section A...
janv. 11 - Charles River to Suspend Operati...
mars 22-mars 23 - San Francisco, CA - 2010 PMF Bacterial Endotoxin Summit
avr. 13-avr. 13 - Vienna, Austria - Practice Course: Substance Application and Blood Sa...
view all
Clinical Pathology Analyst Tranent, Scotl...
Health & Safety Officer Tranent, Scotland

Charles River Laboratories, Inc.